<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04920357</url>
  </required_header>
  <id_info>
    <org_study_id>Eudra-CT2021-000683-30</org_study_id>
    <nct_id>NCT04920357</nct_id>
  </id_info>
  <brief_title>Immune Response to Vaccination Against Covid-19, a Follow up Study</brief_title>
  <acronym>CoVacc</acronym>
  <official_title>CoVacc - Immune Response to Vaccination Against Covid-19, an Open Multicenter Phase IV Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Region Västerbotten</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Värmland County Council, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Örebro Läns Landsting</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sormland County Council, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region Jämtland Härjedalen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Umeå University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates the immune response after vaccination in individuals with and without&#xD;
      pre-existing immunity to Coronavirus disease (COVID) -19. The participants are followed and&#xD;
      sampled up to 4 years after vaccination. Blood samples are collected at different timepoints&#xD;
      to analyze immune response.&#xD;
&#xD;
      The aim is to investigate the level of specific antibodies to Severe acute respiratory&#xD;
      syndrome coronavirus 2 (SARS-CoV-2) yearly, up to 4 years after vaccination.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective is to investigate if the antibody development to SARS-CoV-2 S protein&#xD;
      differ after vaccination in those who have had a previous SARS-CoV-2 infection compared to&#xD;
      Covid-19 naive individuals.&#xD;
&#xD;
      The secondary objective is to improve the understanding of the cellular and serological&#xD;
      immune response after vaccination against COVID-19 in these groups.&#xD;
&#xD;
      Individuals with and without pre-existing immunity to COVID-19 are included in the study.&#xD;
      They are included after informed consent at sites where they receive vaccines against&#xD;
      COVID-19 within the national and regional vaccine campaign.&#xD;
&#xD;
      The study includes all approved COVID-19 vaccines with marketing authorization in Sweden.&#xD;
&#xD;
      Persons are enrolled after the first or second dose of vaccination and followed 4 years after&#xD;
      vaccination. Blood is collected at inclusion and 3 months, 6 months, 1 year, 2 years, 3 years&#xD;
      and 4 years after vaccination to assess the immune response.&#xD;
&#xD;
      Data on sex, age, body mass index, medical history and concomitant medication is collected.&#xD;
&#xD;
      The study is a follow-up study after vaccination and approved by the Swedish Medical Products&#xD;
      Agency (EudraCT 2021-000683-30). Regular monitoring of the study is performed by the Clinical&#xD;
      Trial unit at Umeå University Hospital.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Years</target_duration>
  <primary_outcome>
    <measure>Change in levels of specific IgG antibody against SARS-CoV-2 after vaccination over time.</measure>
    <time_frame>1 and 6 months, 1, 2, 3, and 4 years after vaccination.</time_frame>
    <description>Levels of specific IgG antibody against SARS-CoV-2 will be measured as optical density, OD in a specific Spike-protein IgG ELISA at each time-point.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in proportion of participants with detectable specific IgG antibodies after vaccination over time.</measure>
    <time_frame>1 and 6 months, 1, 2, 3, and 4 years after vaccination</time_frame>
    <description>Immune response will be measured as the proportion of participants (in % of all vaccinated individuals) with detectable specific IgG antibodies after vaccination at each time-point (in months after vaccination).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levels of markers for immune response after infection and vaccination against COVID-19 in COVID-naive versus COVID experienced individuals.</measure>
    <time_frame>Change of markers for cellular and serological immune response over time measured at 1 and 6 months, 1, 2, 3, and 4 years after vaccination</time_frame>
    <description>Levels of markers for cellular and serological immune response after COVID-19 vaccination e.g. specific antibodies, T- and B-cell memory.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Vaccination; Infection</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Post-COVID-19</arm_group_label>
    <description>Persons with a verified previous COVID-19 infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COVID-19 naive</arm_group_label>
    <description>Persons that have no history of COVID-19</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaccination</intervention_name>
    <description>Persons that are vaccinated within the national and regional vaccine program are invited to participate in the follow-up study.</description>
    <arm_group_label>COVID-19 naive</arm_group_label>
    <arm_group_label>Post-COVID-19</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Periferal blood mononuclear cells (PBMC), plasma and sera.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with and without pre-existing immunity to Covid-19 that are vaccinated in the&#xD;
        national and regional vaccine campaign.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consents to participate in the study&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Incapable of giving informed consent&#xD;
&#xD;
          -  Contraindication to vaccination&#xD;
&#xD;
          -  Severe disease&#xD;
&#xD;
          -  Ongoing treatment that is judged to affect the vaccine response (Does not include&#xD;
             Rituximab which is allowed after individual consideration). Steroids &gt; 15 mg orally&#xD;
             per day.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clas Ahlm, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Umeå University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clas Ahlm, Prof</last_name>
    <phone>+46-(0)70-3172965</phone>
    <email>clas.ahlm@umu.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mattias Forsell, Assoc Prof</last_name>
    <phone>+46-(0)73-0211221</phone>
    <email>mattias.forsell@umu.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mälarsjukhuset</name>
      <address>
        <city>Eskilstuna</city>
        <zip>633 49</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Kalén, MD</last_name>
      <phone>+46 (0)16-10 30 00</phone>
      <email>markus.kalen@regionsormland.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karlstad Central hospital</name>
      <address>
        <city>Karlstad</city>
        <zip>651 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Staffan Tevell, PhD</last_name>
      <phone>+46 (0) 10-8315000</phone>
      <email>staffan.tevel@regionvarmland.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Umeå University hospital</name>
      <address>
        <city>Umeå</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Normark, Assoc Prof</last_name>
      <phone>+46- (0) 70-2258959</phone>
      <email>johan.normark@umu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Örebro University hospital</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anja Rosdahl, MD</last_name>
      <phone>+46- (0)19-602 10 00</phone>
      <email>anja.rosdahl@regionorebrolan.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Östersund hospital</name>
      <address>
        <city>Östersund</city>
        <zip>831 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Micael Widerström, Assoc Prof</last_name>
      <phone>+46 (0)63-15 30 00</phone>
      <email>micael.widerstrom@umu.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>June 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immune response</keyword>
  <keyword>Immunoglobulin G</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

